Phathom Pharmaceuticals (PHAT) Competitors

ACADIA Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, ACADIA Pharmaceuticals had 10 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 21 mentions for ACADIA Pharmaceuticals and 11 mentions for Phathom Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.20 beat Phathom Pharmaceuticals' score of -0.08 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals has a net margin of 36.49% compared to Phathom Pharmaceuticals' net margin of -76.77%. ACADIA Pharmaceuticals' return on equity of 12.49% beat Phathom Pharmaceuticals' return on equity.

ACADIA Pharmaceuticals currently has a consensus target price of $31.21, suggesting a potential upside of 38.25%. Phathom Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 104.42%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

Twist Bioscience has higher revenue and earnings than Phathom Pharmaceuticals. Twist Bioscience is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, Twist Bioscience had 11 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 22 mentions for Twist Bioscience and 11 mentions for Phathom Pharmaceuticals. Twist Bioscience's average media sentiment score of 0.14 beat Phathom Pharmaceuticals' score of -0.08 indicating that Twist Bioscience is being referred to more favorably in the media.

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Twist Bioscience has a net margin of -19.85% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Twist Bioscience's return on equity.

Twist Bioscience currently has a consensus price target of $56.57, suggesting a potential downside of 3.36%. Phathom Pharmaceuticals has a consensus price target of $25.00, suggesting a potential upside of 104.42%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Twist Bioscience.

Twist Bioscience has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.

Phathom Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has a net margin of 36.39% compared to Phathom Pharmaceuticals' net margin of -76.77%. Catalyst Pharmaceuticals' return on equity of 36.47% beat Phathom Pharmaceuticals' return on equity.

Catalyst Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Phathom Pharmaceuticals presently has a consensus price target of $25.00, suggesting a potential upside of 104.42%. Catalyst Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 6.94%. Given Phathom Pharmaceuticals' higher possible upside, equities analysts clearly believe Phathom Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

In the previous week, Catalyst Pharmaceuticals had 5 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 16 mentions for Catalyst Pharmaceuticals and 11 mentions for Phathom Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.20 beat Phathom Pharmaceuticals' score of -0.08 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

In the previous week, Phathom Pharmaceuticals had 3 more articles in the media than Organon & Co.. MarketBeat recorded 11 mentions for Phathom Pharmaceuticals and 8 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.39 beat Phathom Pharmaceuticals' score of -0.08 indicating that Organon & Co. is being referred to more favorably in the news media.

Phathom Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Organon & Co. has a net margin of 3.99% compared to Phathom Pharmaceuticals' net margin of -76.77%. Organon & Co.'s return on equity of 99.95% beat Phathom Pharmaceuticals' return on equity.

Organon & Co. has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Phathom Pharmaceuticals presently has a consensus price target of $25.00, suggesting a potential upside of 104.42%. Organon & Co. has a consensus price target of $11.40, suggesting a potential downside of 14.57%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Phathom Pharmaceuticals is more favorable than Organon & Co..